Journal of Pediatric Endocrinology and Metabolism · 2013 · 23 citations · 0 references
MedicineEndocrinologyPediatricsHepatologyNeonatologyPediatric EndocrinologyLiver DiseaseMetabolic Liver DiseaseNeonatal HypoglycemiaNeonatal Metabolic DisordersPediatric HepatologyPediatric Liver DiseaseDiazoxide TherapyNeonatal HepatitisOctreotide TherapyPersistent Hyperinsulinemic HypoglycemiaPersistent HypoglycemiaPersistent Neonatal HypoglycemiaSomatostatin Analog TherapySomatostatin Analogues
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), the most common cause of persistent hypoglycemia in the neonatal period and infancy, is a genetic disorder characterized by abnormal regulation of insulin secretion. Octreotide, a somatostatin analog, is often used as a second-line treatment when diazoxide therapy fails to control hypoglycemia. We report herein a rare development of octreotide-induced hepatitis following prolonged treatment for PHHI in an infant. Octreotide-induced hepatitis may occur mostly when high doses are given, or when dosing is increased. This warrants routine examination of liver function. When hepatitis develops, prompt cessation of octreotide therapy will probably result in subsequent resolution.